Real-time polymerase chain reaction tests versus antenatal culture tests for the screening of maternal group B Streptococcus colonisation in labour by Seedat, Farah et al.
Citation:  Seedat,  Farah,  Cooper,  Jennifer  A,  Uthman,  Olalekan  A,  Takwoingi,  Yemisi, 
Robinson, Esther R, Kandala, Ngianga-Bakwin, Stranges, Saverio and Taylor-Phillips, Sian 
(2018)  Real-time  polymerase  chain  reaction  tests  versus  antenatal  culture  tests  for  the 
screening of maternal group B Streptococcus colonisation in labour. Cochrane Database of 
Systematic Reviews, 2018 (5). CD013016. ISSN 1465-1858 
Published by: Wiley
URL:  https://doi.org/10.1002/14651858.CD013016 
<https://doi.org/10.1002/14651858.CD013016>
This  version  was  downloaded  from  Northumbria  Research  Link: 
http://nrl.northumbria.ac.uk/38141/
Northumbria University has developed Northumbria Research Link (NRL) to enable users to 
access the University’s research output. Copyright ©  and moral rights for items on NRL are 
retained by the individual author(s) and/or other copyright owners.  Single copies of full items 
can be reproduced,  displayed or  performed,  and given to third parties in  any format  or 
medium for personal research or study, educational, or not-for-profit purposes without prior 
permission or charge, provided the authors, title and full bibliographic details are given, as 
well  as a hyperlink and/or URL to the original metadata page.  The content must  not  be 
changed in any way. Full  items must not be sold commercially in any format or medium 
without  formal  permission  of  the  copyright  holder.   The  full  policy  is  available  online: 
http://nrl.northumbria.ac.uk/policies.html
This document may differ from the final, published version of the research and has been 
made available online in accordance with publisher policies. To read and/or cite from the 
published version of the research, please visit the publisher’s website (a subscription may be 
required.)
Cochrane Database of Systematic Reviews
Real-time polymerase chain reaction tests versus antenatal
culture tests for the screening of maternal group B
Streptococcus colonisation in labour (Protocol)
Seedat F, Cooper JA, Uthman OA, Takwoingi Y, Robinson ER, Kandala NB, Stranges S, Taylor-
Phillips S
Seedat F, Cooper JA, Uthman OA, Takwoingi Y, Robinson ER, Kandala NB, Stranges S, Taylor-Phillips S.
Real-time polymerase chain reaction tests versus antenatal culture tests for the screening of maternal group B Streptococcus colonisation
in labour.
Cochrane Database of Systematic Reviews 2018, Issue 5. Art. No.: CD013016.
DOI: 10.1002/14651858.CD013016.
www.cochranelibrary.com
Real-time polymerase chain reaction tests versus antenatal culture tests for the screening of maternal group B Streptococcus
colonisation in labour (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
5OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
23SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iReal-time polymerase chain reaction tests versus antenatal culture tests for the screening of maternal group B Streptococcus
colonisation in labour (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Diagnostic Test Accuracy Protocol]
Real-time polymerase chain reaction tests versus antenatal
culture tests for the screening of maternal group B
Streptococcus colonisation in labour
Farah Seedat1, Jennifer A Cooper1, Olalekan AUthman2, Yemisi Takwoingi3 , Esther R Robinson4 , Ngianga-Bakwin Kandala5, Saverio
Stranges6, Sian Taylor-Phillips1
1Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK. 2Warwick Centre for Applied Health
Research and Delivery (WCAHRD), Division of Health Sciences, Warwick Medical School, The University of Warwick, Coventry,
UK. 3Institute of Applied Health Research, University of Birmingham, Birmingham, UK. 4Birmingham Public Health Laboratory,
Heartlands Hospital, Birmingham, UK. 5Department of Mathematics, Physics & Electrical Engineering (MPEE), Faculty of Engineer-
ing and Environment, Northumbria University, Newcastle upon Tyne, UK. 6Department of Epidemiology and Biostatistics, Schulich
School of Medicine and Dentistry, Western University, London, Canada
Contact address: Farah Seedat, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, CV4 7AL,
UK. f.seedat@warwick.ac.uk, farah.rseedat@gmail.com.
Editorial group: Cochrane Pregnancy and Childbirth Group.
Publication status and date: New, published in Issue 5, 2018.
Citation: Seedat F, Cooper JA, Uthman OA, Takwoingi Y, Robinson ER, Kandala NB, Stranges S, Taylor-Phillips S. Real-time
polymerase chain reaction tests versus antenatal culture tests for the screening of maternal group B Streptococcus colonisation in labour.
Cochrane Database of Systematic Reviews 2018, Issue 5. Art. No.: CD013016. DOI: 10.1002/14651858.CD013016.
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
The primary objective is to compare the diagnostic accuracy of commercially available real-time polymerase chain reaction (PCR) tests
and antenatal culture tests for diagnosing group B Streptococcus (GBS) colonisation in pregnant women during labour.
B A C K G R O U N D
Target condition being diagnosed
Group B Streptococcus (GBS), or Streptococcus agalactiae, was first
identified as a serious child health concern in the 1960s, when
it was found to be the leading cause of neonatal sepsis (Baker
1973). GBS is a naturally occurring Gram-positive Streptococcal
bacterium that intermittently colonises the gastrointestinal and
genitourinary tract in 30% of healthy adults (Edwards 2010;
Edwards 2011; Rodriguez-Granger 2012). As such, GBS colonises
the vagina in 10% to 30% of pregnant women (Daniels 2009).
If a pregnant woman is vaginally colonised with GBS when she
is in labour, there is approximately a 50% risk that GBS can be
transmitted to the newborn, either through the newborn passing
the colonised birth canal, or GBS ascending in utero (Brocklehurst
2005; Colbourn 2007a). Most of these GBS colonised babies will
be asymptomatic, however approximately 1% to 2% will suffer
from invasive GBS disease (Boyer 1985), and approximately 10%
of babies with invasive GBS disease will die as a result of it (Heath
2004; Verani 2010a).
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Invasive GBS disease is separated into early-onset GBS (EOGBS)
and late-onset GBS (LOGBS). EOGBS occurs during the first
seven days of life, with 90% of cases presenting within 24 hours
(Heath 2004). EOGBS cases progress rapidly, presenting with sep-
sis in 63% of cases or pneumonia in 26% (Daniels 2009; Heath
2004). LOGBS presents between seven and 90 days after birth and
is less progressive; it is associated with localised infections, partic-
ularly meningitis (43%), pneumonia or focal infections (Daniels
2009; Heath 2004). EOGBS is associated with higher morbidity
and mortality than LOGBS (Edmond 2012; Feldman 1992). In
the 1970s, case fatality rates fromEOGBSwere 20% to 50%; these
have substantially declined to 4% to 10%, a decrease attributed
to treatment (Rodriguez-Granger 2012; Verani 2010a).
Current global incidence of neonatal GBS is estimated to be 0.53
per 1000 live births (95% confidence interval (CI) 0.44 to 0.62)
with case fatality at 9.6% (95%CI 6.2 to 18.3), although this inci-
dence is likely to be an underestimate (Edmond 2012). GBS bur-
den varies geographically, with the highest incidence per 1000 live
births found in Africa (1.21), followed by the Americas (0.67), Eu-
rope (0.57), EasternMediterranean (0.35),Western Pacific (0.15),
and very low estimates in Southeast Asia (0.016) (Edmond 2012).
EOGBS incidence is estimated at 0.43 per 1000 live births, with
12.1% case fatality, while LOGBS incidence is 0.24 per 1000 live
births with 6.8% case fatality (Edmond 2012). Incidence of GBS
also varies widely by country. For example, during the 1980s, the
incidence of EOGBS in the USA was between one and three per
1000 live births (Boyer 1985; Rodriguez-Granger 2012; Schrag
2002), which decreased to 0.24 per 1000 live births with the in-
troduction of prevention (CDC 2013), whereas in the UK the
incidence of EOGBS is approximately at 0.48 per 1000 live births
with a case fatality of 5% to 10% (Heath 2004; Lamagni 2013).
To prevent EOGBS, many countries recommend offering intra-
partum antibiotic prophylaxis (IAP) tomothers to prevent vertical
transmission (Boyer 1986; Verani 2010a). IAP was first demon-
strated to be effective in reducing EOGBS in 1986 (Boyer 1986).
An updated Cochrane review has also found that IAP substan-
tially decreases the incidence of culture confirmed and probable
EOGBS, compared to no treatment (Ohlsson 2014). However,
the authors found a high risk of bias across the randomised con-
trolled trials (RCTs) and concluded that the results could therefore
be due to the bias in methodology. They did not find any evidence
that IAP reduces neonatal mortality from GBS compared to no
treatment. Different prevention strategies have been proposed to
identify women at risk of having a baby with EOGBS, so that tar-
geted IAP can be offered (RCOG 2012; Rodriguez-Granger 2012;
Verani 2010a). One of these strategies involves assessing women
for GBS risk factors during labour, while another involves actively
screening all women for GBS carriage during pregnancy (RCOG
2012; Verani 2010b). A universal antenatal screening strategy was
first adopted in the US in 1996 by the Centers for Disease Con-
trol and Prevention (CDC), and many European countries fol-
lowed this example, including France, Germany, Spain and Italy
(Rodriguez-Granger 2012). No RCT evidence is available on GBS
screening, but observational evidence from countries that have im-
plemented screening has shown that screening is associated with a
lower incidence of EOGBS compared to risk-based prevention or
no prevention (CDC 2013; Taminato 2011). Without RCT evi-
dence, it is difficult to calculate the impact of antenatal screening
due to confounding factors.
Index test(s)
It is important to note that the aim of GBS testing is to prevent
GBS disease in newborn babies. However, tests that are currently
available do not discriminate between colonised mothers who will
or will not transmit GBS to their babies, or between babies who
will or will not suffer from GBS disease. Instead there are several
methods for identifying GBSmaternal colonisation in labour, and
some of these GBS-positive women will not give birth to GBS
infected babies. The gold standard for detecting GBS colonisa-
tion in labour is considered to be intrapartum bacterial culture.
However, because bacterial culture takes 24 to 48 hours to pro-
cess, culture is not feasible to use in labour because results cannot
be available in time to treat. Instead, bacterial culture has to be
performed antenatally. Traditionally, screening programmes cul-
ture vaginal or vagino-rectal swabs at 35 to 37 weeks, as this has
been identified as the optimal time to test for GBS, to take into
account changes in colonisation status and provide sufficient time
to obtain results (Schrag 2002; Verani 2010a). However, a system-
atic review published in 2010 demonstrated that in prospective
studies, around 30% of women with a positive GBS culture at 35
weeks or more had changed to negative by birth (Valkenburg-van
den Berg 2010).
Culture testing involves plating vaginal or vagino-rectal (more sen-
sitive) swabs on blood agar plates where, if a woman is colonised,
GBS grows, forming white colonies surrounded by β-haemolysis
areas (Daniels 2009). This woman will therefore be diagnosed as
positive forGBS colonisation. If theGBS colonies do not grow, the
woman is diagnosed as negative forGBS colonisation. Selective en-
richment broth before plating is recommended to improve the iso-
lation of GBS from swabs by 50%, although its necessity has been
questioned (CDC 1999; Daniels 2009). The most widely used
enrichment media is Lim broth with Todd-Hewitt base, nalidixic
acid, and colistin before plating on blood agar (Daniels 2009).
The site of swab, timing of swab and use of selective media can
vary the detection of GBS colonisation (Schrag 2002). As GBS
colonisation may be transient, antenatal culture is not very accu-
rate at predicting GBS vaginal colonisation in labour. The sys-
tematic review in 2010 found sensitivity ranging from 42.8% to
100% and specificity ranging from 49% to 100%, a mean positive
predictive value (PPV) of 69% (ranging from 43% to 100%) and
a mean negative predictive value (NPV) of 94% (ranging from
80% to 100%), using intrapartum culture as the reference stan-
dard (Valkenburg-van den Berg 2010). The mean antenatal GBS
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prevalence was 18% and the mean intrapartum GBS prevalence
was 20%.
As a result of the limitations in culture methods, rapid testing
methods have been developed, where women found to be GBS
carriers during labour can be offered IAP. In addition to being
accurate, rapid tests need to be timely enough to allow prompt
and effective IAP treatment, and need to be easy to use in routine
practice in busy maternity wards. A systematic review (Honest
2006), and a subsequent study (Daniels 2009), found that out of
all the rapid tests available, real-time polymerase chain reaction
(PCR) testing was the most promising. The remaining rapid tests
(see alternative tests below) took too long to achieve a result or
did not have adequate test accuracy (Daniels 2009; Honest 2006).
Similarly, a literature review for the development of European
consensus guidelines reported that the other rapid tests showed
poor sensitivity, ranging from 33% to 65% (Di Renzo 2014).
Real-time PCR for GBS involves amplification and detection of
GBS-specific DNA. A vaginal or vagino-rectal swab is taken (en-
riched or standard) and DNA extracted. The specific areas of the
bacterial chromosome are targeted by primers and undergo loga-
rithmic iterative amplification, in order to identify whether there
is any evidence of GBS DNA (Daniels 2009). In some older real-
time PCR tests, such as LightCycler (Idaho Technology), Smart-
Cycler (Cepheid), and IDI-Strep B (Somagen), a swab has to be
prepared first, before it can be placed into the real-time PCR ma-
chine for analysis. Preparation includes extracting the bacterial
DNA from the swab and adding the primer and polymerase. Pos-
itive and negative controls also have to be prepared for each kit
to ensure biases and false results are avoided (Alfa 2010; Daniels
2009). The samples are then inserted into the PCRmachine where
the target DNA for GBS is amplified, and the presence of GBS
is detected from fluorescent signals (Alfa 2010; Daniels 2009).
More recently, the GeneXpert GBS (Cepheid) automatically in-
tegrates the whole process of DNA extraction, amplification, and
detection in the GeneXpert GBS machine. A vagino-rectal swab
is inserted into a single-use cartridge in the machine that contains
the PCR reagents and controls to process and analyse the swab
(Helali 2009; NICE 2015; Park 2013). The results for any of the
real-time PCR tests present as positive, negative or inhibitory (i.e.
results are inconclusive and the patient needs to be re-tested). Each
commercially available GBS real-time PCR assay can target dif-
ferent genes for GBS, use different methods for DNA extraction,
and have a different number of cycles for DNA amplification. Any
rapid intrapartum test needs to be rapid enough for sufficient time
to deliver IAP in labour. The average time to complete a real-time
PCR test is 40 to 50 minutes (Honest 2006; NICE 2015).
The previous systematic review found real-time PCR to have ame-
dian sensitivity of 96% and specificity of 98% across two studies
when a) anal, b) lower vaginal, and c) anal and lower vaginal intra-
partum culture were used as a reference (Honest 2006). Since the
report, there have been varying estimates of diagnostic accuracy
for real-time PCR, with sensitivity ranging from 79% to 92% and
specificity from 95% to 98% (Bazian Ltd 2012). The disadvan-
tage of real-time PCR is that it is unable to determine antibiotic
susceptibility, which directs the choice of antibiotic to use for IAP
in women who are allergic to penicillin. Methods to determine
antibiotic susceptibility are culture-based, and as indicated earlier,
cannot be conducted in sufficient time to direct antibiotic selec-
tion if GBS colonisation was only identified by real-time PCR in
labour.
Clinical pathway
To prevent EOGBS disease and mortality in newborn babies, the
current recommendation in the UK is to asses women for known
maternal GBS risk factors, and offer IAP to those who have one
or more risk factors (NICE 2012; RCOG 2012). Risk factors
include; intrapartum fever, incidental GBS, GBS bacteriuria, and
a previous baby with GBS disease (NICE 2012; RCOG 2012).
However, a third of babies with EOGBS disease are born towomen
with no GBS risk factors, who therefore would not have been
offered IAP (Bazian Ltd 2012). Likewise, not all women with GBS
risk factors will transmit GBS to their newborn babies. Screening
for GBS is not recommended in the UK (Bazian Ltd 2012; NICE
2012; RCOG 2012).
In the US, and other countries that actively screen all pregnant
women for GBS, the most commonly used test is antenatal cul-
ture, typically administered between 35 to 37 weeks of pregnancy,
and before the onset of labour (Schrag 2002). IAP is then offered
to all women with positive antenatal culture results, though not
all women will be positive at labour when IAP treatment would be
given (Valkenburg-van den Berg 2010). The most recent recom-
mendation from the CDC on GBS screening suggested that rapid
tests, such as real-time PCR, could be combined with antenatal
culture testing in settings where it is available (Verani 2010b). A
European consensus group has expanded this into a recommen-
dation for intrapartum GBS screening (Di Renzo 2014). In such
a programme, real-time PCR would be administered in labour,
to all women who do not present with risk factors. Those who
are positive would be offered IAP treatment. Women who present
with risk factors would not be screened, and would be treated with
IAP immediately. Antenatal culture testing would only be offered
to women with a history of penicillin allergy, in order to assess
susceptibility to antibiotic agents. In this way, an effective antibi-
otic can be selected for IAP treatment, should the patient go on
to receive a positive real-time PCR result in labour.
As real-time PCR can be administered at the time of treatment, it
is possible that it is more accurate than antenatal culture and can
therefore reduce the number of women receiving IAP unnecessar-
ily. If so, real-time PCR could potentially replace antenatal cul-
ture for the majority of pregnant women, with only those women
who are allergic to penicillin requiring antenatal culture. Real-time
PCR may also benefit the risk-based prevention pathway imple-
mented in the UK. By administering real-time PCR to women
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with risk factors, and only offering IAP to those with a risk factor
and a positive real-time PCR result, it may be possible to reduce
the number of women who receive IAP for GBS (NICE 2015).
Safely reducing unnecessary IAP would be especially useful, as a
number of potential harms have been associated with widespread
IAP usage, including Gram-negative infections, antimicrobial re-
sistance, gut microbiota alterations which may be associated with
long-term health problems, maternal anaphylaxis, and the medi-
calisation of labour (Bazian Ltd 2012; Colbourn 2007b; RCOG
2012). However, real-time PCR would need to demonstrate su-
perior test accuracy, feasibility, and timeliness before it could be
implemented in practice.
For a visual representation of where these tests fit into the clinical
pathway, see Figure 1.
Figure 1. Clinical and research pathwayBlue arrows show the clinical pathway. Red arrows show the
research pathway to assess the diagnostic accuracy.Footnotes:EOGBS: early-onset GBSGBS: group B
StreptococcusPCR: polymerase chain reaction
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Alternative test(s)
Other rapid tests available for GBS detection include optical im-
munoassay (OIA), DNA hybridisation, enzyme immunosorbent
assay (ELISA), latex agglutination as well as conventional PCR
(Daniels 2009). However, we will not evaluate the clinical perfor-
mance of these tests in this review; as real-time PCR and culture
tests are the most used and relevant in clinical practice, we will
focus our review on these tests. Latex agglutination, DNA hybridi-
sation, and ELISA tests are not used in practice, and real-time
PCR was found to be most accurate and effective in a previous
review (Honest 2006), and more accurate than OIA in a previous
diagnostic accuracy study (Daniels 2009). Compared with real-
time PCR, conventional PCR is more time-consuming and less
sensitive.
Rationale
GBS is a significant health problem which can cause fatal compli-
cations in newborn babies (Heath 2004; Verani 2010a). Currently,
the only strategies available to prevent EOGBS disease in new-
borns is to identify and treat pregnant women with antibiotics in
labour (NICE 2012; RCOG 2012; Verani 2010b). Screening, in
particular, is complicated by transient colonisation which means
that over 30% of women could be unnecessarily treated with an-
tibiotics in a climate of increasing antibiotic resistance (Bazian Ltd
2012; Valkenburg-van den Berg 2010).
Real-time PCR tests are available and their use in pregnant women
may increase diagnostic accuracy in screening and risk-based pro-
grammes, and therefore reduce unnecessary antibiotic usage and
its potential harms across countries (Daniels 2009; Honest 2006;
NICE 2015). However, studies on real-time PCR have shown
varying results and the search for the last systematic review on
the diagnostic accuracy of real-time PCR was implemented over
10 years ago in 2005 (Honest 2006). There is a need to update
the systematic review and compare real-time PCR with antenatal
culture. This systematic review will aim to incorporate new evi-
dence to compare the clinical performance of commercially avail-
able real-time PCR tests and antenatal culture tests to diagnose
GBS colonisation in pregnant women in labour.
It is important to note that the outcome of most interest for a GBS
screening programme is not intrapartum culture, but GBS disease
in the newborn. However, we could not investigate this as neonatal
GBS is a prognostic outcome that likely depends on many factors,
including conditions during birth and maternal treatment.
O B J E C T I V E S
The primary objective is to compare the diagnostic accuracy of
commercially available real-time polymerase chain reaction (PCR)
tests and antenatal culture tests for diagnosing group B Streptococ-
cus (GBS) colonisation in pregnant women during labour.
Secondary objectives
To investigate potential sources of heterogeneity in the diagnostic
accuracy of the real-time PCR tests and antenatal culture tests.
This will include variations in: type of intrapartum culture ref-
erence standard used, prevalence rate, and high or low GBS risk
population.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include retrospective and prospective cohort and cross-
sectional studies that evaluated the diagnostic accuracy of com-
mercially available real-time polymerase chain reaction (PCR) tests
or antenatal culture tests, or both, compared with the reference
standard of intrapartum culture. We will include relevant studies
irrespective of whether they assessed PCR and antenatal culture
alone or in combination with other tests.
We will exclude diagnostic case-control studies assessing healthy
versus group B Streptococcus (GBS) colonised individuals, as results
from such studies may overestimate diagnostic accuracy (Lijmer
1999).
Participants
Wewill include studies of women during pregnancy (for antenatal
culture) and labour (for real-time PCR), regardless of age and
ethnicity.
We will include studies conducted in any setting, typically ante-
natal care, labour and delivery care.
Index tests
We will include only studies of commercially available real-time
PCR tests or antenatal culture tests. We will exclude studies
in which antenatal culture tests were administered to pregnant
women before the third trimester, as tests before the third trimester
are too early to be used for detecting intrapartum GBS colonisa-
tion.
Target conditions
We will include studies that diagnose GBS colonisation in preg-
nant women in labour.
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Reference standards
Wewill only include studies that used intrapartum culture to diag-
nose GBS colonisation in pregnant women in labour, with vaginal
or vagino-rectal culture on a blood agar plate using standard or
enriched media broth in a microbiology laboratory.
We will exclude studies in which intrapartum antibiotic prophy-
laxis was given prior to the index test or reference standard being
administered.
Search methods for identification of studies
Electronic searches
Scoping searches have beenundertaken to inform the development
of the search strategy. An iterative procedure was used, with input
from all the authors, amedical librarian, the Information Specialist
from the Cochrane Pregnancy and Childbirth group, previous
systematic reviews and the Cochane Handbook for Systematic
Reviews of Diagnostic Test Accuracy (Deeks 2010).We will search
the following bibliographic databases:
• MEDLINE (Ovid);
• MEDLINE In-Process & Other Non-Indexed Citations
(Ovid);
• EMBASE (Ovid);
• Cochrane CENTRAL, DARE and HTA databases (Wiley);
• Science Citation Index and Conference Proceedings (Web
of Science); and
• Cumulative Index to Nursing and Allied Health Literature
(Ebscohost).
Auto alerts will be run in Medline and Embase from the date of
the searches to identify relevant new studies.
The search strategy combines three sets of search terms using both
text words and controlled terms through boolean operators OR
within each set and then AND to combine the sets. The first
set is made up of search terms for real-time PCR or culture, the
second set is made up of search terms for GBS, the third set is
made up of search terms for women who are pregnant or in labour.
The search strategy is not limited to any date or language. Non-
English language papers will be translated into English. We have
adapted the search strategy to suit each database. The detailed
search strategies can be found in Appendix 1. We will record the
date of the search and the number of search results for each search
line.
We will also search the following trial registers: ISRCTN registry,
UK Clinical Trials Gateway, ClinicalTrials.gov, and the WHO
International Clinical Trials Registry Platform (ICTRP).
Searching other resources
We will handsearch reference lists of included studies and relevant
systematic reviews identified through the database searches. We
will also invite international experts on GBS to provide further
references or conference proceedings that may be additional to our
included lists of references from the database searches.
Data collection and analysis
The following methods section of this protocol is based on a stan-
dard template used by the Cochrane Pregnancy and Childbirth
Group.
Selection of studies
Two authors (FS, JC) will independently screen the titles and ab-
stracts of all identified bibliographic records for relevance (screen-
ing level 1). Afterwards, the two authors will retrieve full-text re-
ports of all potentially relevant records identified at screening level
1 and review them using the same study eligibility criteria (screen-
ing level 2). Any disagreements over inclusion or exclusion will be
resolved by discussion between two review authors or arbitration
by a third review author. We will document the study flow and
reasons for exclusion of full-text papers in a PRISMA study flow
diagram (Moher 2009).
Data extraction and management
For each included study, two authors (FS, JC) will independently
extract relevant data using an a priori defined and piloted data ex-
traction sheet using Google Forms. We will cross-check extracted
data, and any disagreements will be resolved by discussion or arbi-
tration by a third author. If information is unclear, we will contact
study authors for further explanation. The data we extract will
include the following.
• Study characteristics: first author, country, publication year,
setting, number of sites, sources of funding, sources of trial
funding, methodological quality, recruitment dates, trial authors’
conflicts of interest
• Participants: method of participant selection, inclusion and
exclusion criteria, number of eligible participants, number
enrolled, number who received both tests, number results
available, number of excluded participants, mother and
gestational age, ethnicity, prevalence of GBS colonisation,
number of high risk GBS, GBS case load, inclusion of elective
caesarean section
• Reference standard: type of tests used for identification of
GBS colonisation, timing of tests, site of tests, culture medium,
laboratory transfer, definition of positivity/negativity, other
methods of laboratory analysis used for derivation of test results,
blinding
• Index test: type of tests used for identification of GBS
colonisation (real-time PCR, antenatal culture, or both), type of
real-time PCR test, timing of tests, site of tests, laboratory
transfer, culture medium, target gene, DNA extraction method,
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threshold cycle, definition of positivity/negativity, other methods
of laboratory analysis used for derivation of test results, blinding
• Diagnostic accuracy outcomes: number of true positives,
false positives, true negatives and false negatives, and number of
indeterminate/invalid test results or test failures for each test
Assessment of methodological quality
Two authors (FS, JC)will independently assess themethodological
quality of each study using a modified and piloted QUADAS-2
instrument (Appendix 2) (Whiting 2011). We have tailored the
tool to our review question, developing review-specific guidance
on how to assess each signalling question and how to use this
information to judge risk of bias and applicability (Appendix 2).
We will assess each signalling question as ’yes’, ’no’, or ’unclear’
(inadequate detail presented to allow a judgement to be made)
risk of bias. Each domain will then be judged to be at ’low’, ’high’,
or ’unclear’ risk of bias, based on review-specific guidance that we
have developed on the sources of bias that are most important for
GBS screening tests (Appendix 2). We will resolve any disagree-
ments through consensus or through discussion with a third au-
thor.We will summarise the methodological quality assessment of
included studies in a table or summary graphs (or both).
Statistical analysis and data synthesis
Using Review Manager 5 (RevMan 2014), we will plot estimates
of sensitivity and specificity for each test on forest plots and in re-
ceiver-operating characteristic (ROC) space, to explore differences
in test performance between studies.
Antenatal culture tests differ from real-time PCR tests in that real-
time PCR tests can have different thresholds (cycles of amplifi-
cation within which test results are valid), whereas antenatal cul-
ture tests do not have different thresholds. Therefore, we will use
hierarchical summary receiver-operating characteristic (HSROC)
models for meta-analysis to enable estimation of summary curves
where between-study variation could be explained by threshold
variation (Rutter 2001). Given the relationship between bivariate
and HSROC models (Harbord 2007), we will also use this model
to estimate summary points where studies have used a common
threshold. However, if studies typically report a common thresh-
old for real-time PCR tests, we will use the bivariate model (Chu
2006; Reitsma 2005) instead of the HSROC model for all anal-
yses. For the summary ROC curves, sensitivities will be deduced
for a fixed specificity of 95%.
To compare test accuracy, we will perform indirect comparisons
using all relevant studies, as well as direct comparisons restricted
to studies that compared tests in the same study population. Hi-
erarchical meta-regression models incorporating test type as a co-
variate will be used for the analyses. If the HSROCmodel is used,
we will assess the effect of test type on the accuracy, threshold and/
or shape parameters. Alternatively, if the bivariate model is used
we will assess association of test type with sensitivity specificity or
both. If there are enough studies to permit fitting of more complex
models, we will also assess the effect of test type on the variance
parameters of the hierarchical (HSROC or bivariate) models. All
the analyses will be performed by comparing the accuracy of dif-
ferent commercially available brands of real-time PCR test with
antenatal tests. As predictive values are useful to policy makers, we
will use the approach described in Bossuyt 2013 to obtain predic-
tive values and their confidence intervals using summary estimates
of sensitivity and specificity and likelihood ratios derived from the
meta-analyses, together with the median GBS prevalence across
studies for each target condition.
We will fit HSROC models using the NLMIXED procedure in
SAS version 9.4 (SAS 2017). Although bivariate models can also
be fitted using NLMIXED, we will use themeqrlogit command in
Stata 15 (Stata 2017) because in our experiencemodel convergence
problems occur less frequently when fitting the bivariate model in
Stata.
Investigations of heterogeneity
To formally investigate potential sources of heterogeneity, we will
perform meta-regression by incorporating each covariate in a hi-
erarchical model. If sufficient studies are available, we will address
the following.
• Reference standard
For GBS colonisation at labour, the primary reference standard is
intrapartum culture. However, the following parameters can affect
the accuracy of culture and therefore the accuracy of the different
tests with intrapartum culture: culture medium (standard versus
selective) and site of culture swab (vaginal versus vagino-rectal).
• Prevalence
Diagnostic accuracy may vary with disease prevalence (Leeflang
2009), whereby better performance is shown in populations with
higher prevalence, because of clinical variability in the patients or
artefactual variability due to imperfections in the study design.
If we include a sufficient number of studies, we will categorise
GBS prevalence to represent low-risk (below 10%GBS prevalence
across studies), medium-risk (10% to 30% GBS prevalence across
studies) and high-risk populations (above 30% GBS prevalence
across studies), anduse these categories as a covariate in themodels.
Otherwise we will dichotomise GBS prevalence to represent low-
risk (below 20% GBS prevalence across studies) and high-risk
populations (20% and above GBS prevalence across studies), and
use these categories as covariates in the models.
• Antenatal culture
We will investigate the effect of different parameters that may
affect the accuracy of culture, similar to those shown above for
intrapartum culture (culture medium and site of swab), as well as
timing of the test (e.g. less than 35 weeks, 35 to 37 weeks, more
than 37 weeks).
• High risk of GBS
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As test accuracy can vary with spectrum of disease, we will com-
pare test accuracy in populations with high predisposing risk of
GBS, to the general population and unspecified population, as
identified in the studies. We will define high risk as populations
where pregnant women have either one of the following known
maternal risk factors for GBS: premature delivery, previous baby
with GBS, incidental finding of GBS in current pregnancy, ma-
ternal fever, and prolonged rupture of membranes (PROM). We
will define the general population where it is stated as such in the
study, and for studies where nothing is stated, we will define the
population as unspecified. This analysis will only be conducted if
there is a sufficient number of studies that report test accuracy in
populations with these high predisposing risk factors for GBS.
Sensitivity analyses
We will carry out the following sensitivity analyses to explore the
robustness of the result.
• We will only include studies which used selective culture
medium and vagino-rectal swabs as a reference standard for
intrapartum culture.
• We will exclude studies at high or unclear risk of bias
according to the QUADAS-2 assessment (especially in terms of
blinding of reference standard test results, and consecutive
recruitment).
Assessment of reporting bias
We will not assess reporting bias because of current uncertainties
about how to address the issue in test accuracy reviews (Macaskill
2010).
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A P P E N D I C E S




2 exp group B streptococcal infection/
3 strep* adj2 agalact*.ti,ab,kw.
4 strep* adj2 b.ti,ab,kw.




9 exp prenatal care/
10 prenatal period/
11 intrapartum care/
12 exp obstetric delivery/





18 (labour* or labor*).ti,ab,kw.
19 antenatal*.ti,ab,kw.
20 (prenatal* or pre-natal*).ti,ab,kw.
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(Continued)
21 (intrapartum* or intra-partum*).ti,ab,kw.
22 (antepartum* or ante-partum*).ti,ab,kw.
23 deliver*.ti,ab,kw.
24 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25 exp nucleic acid analysis/
26 cultur*.ti,ab,kw.
27 polymerase chain reaction.ti,ab,kw.
28 pcr.ti,ab,kw.
29 medi*.ti,ab,kw.
30 exp culture medium/
31 25 or 26 or 27 or 28 or 29 or 30




2 strep* adj2 b.ti,ab,kw.
3 strep* adj2 agalact*.ti,ab,kw.
4 1 or 2 or 3
5 exp Pregnancy/
6 exp Parturition/
7 exp Labor, Obstetric/
8 Prenatal Care/
9 exp Prenatal Diagnosis/
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(Continued)
10 exp Delivery, Obstetric/
11 Pregnancy Complications, Infectious/
12 Obstetric Labor Complications/
13 Mass Screening/
14 pregnan*.ab,kw,ti.
15 (labour or labor).ab,kw,ti.
16 antenatal*.ab,kw,ti.
17 (prenatal* or pre-natal*).ab,kw,ti.
18 (intrapartum* or intra-partum*).ab,kw,ti.




23 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24 exp Nucleic Acid Amplification Techniques/
25 cultur*.ab,kw,ti.
26 exp Culture Media/
27 polymerase chain reaction.ab,kw,ti.
28 pcr.ab,kw,ti.
29 medi*.ab,kw,ti.
30 24 or 25 or 26 or 27 or 28 or 29
31 4 and 23 and 30
Ovid Medline In-Process & Other Non-Indexed Citations
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Searches
1 strep* adj2 b.ti,ab,kw.
2 strep* adj2 agalact*.ti,ab,kw.
3 Streptococcus agalactiae/
4 1 or 2 or 3
5 exp Pregnancy/
6 exp Parturition/
7 exp Prenatal Diagnosis/
8 pregnan*.ab,kw,ti.
9 birth*.ab,kw,ti.
10 (labour* or labor*).ab,kw,ti.
11 antenatal*.ab,kw,ti.
12 (prenatal* or pre-natal*).ab,kw,ti.
13 (intrapartum* or intra-partum*).ab,kw,ti.




18 exp Labor, Obstetric/
19 Prenatal Care/
20 exp Delivery, Obstetric/
21 Pregnancy Complications, Infectious/
22 Obstetric Labor Complications/
23 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
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(Continued)
24 cultur*.ab,kw,ti.
25 polymerase chain reaction.ab,kw,ti.
26 pcr.ab,kw,ti.
27 exp Nucleic Acid Amplification Techniques/
28 medi*.ab,kw,ti.
29 exp Culture Media/
30 24 or 25 or 26 or 27 or 28 or 29
31 4 and 23 and 30
Wiley Cochrane Database of Systematic Reviews, CENTRAL, DARE, HTA
ID Search
#1 MeSH descriptor: [Streptococcus agalactiae] this term only
#2 strep* adj2 b
#3 strep* adj2 agalact*
#4 #1 or #2 or #3
#5 MeSH descriptor: [Pregnancy] explode all trees
#6 MeSH descriptor: [Parturition] explode all trees
#7 MeSH descriptor: [Labor, Obstetric] explode all trees
#8 MeSH descriptor: [Prenatal Care] this term only
#9 MeSH descriptor: [Prenatal Diagnosis] explode all trees
#10 MeSH descriptor: [Delivery, Obstetric] explode all trees
#11 MeSH descriptor: [Pregnancy Complications, Infectious] this term only
#12 MeSH descriptor: [Obstetric Labor Complications] this term only
#13 MeSH descriptor: [Mass Screening] this term only
#14 pregnan*
#15 labour or labor
#16 antenatal*
#17 prenatal* or pre-natal*
#18 intrapartum* or intra-partum*




#23 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22
#24 MeSH descriptor: [Nucleic Acid Amplification Techniques] explode all trees
#25 cultur*
#26 MeSH descriptor: [Culture Media] explode all trees
#27 polymerase chain reaction
#28 pcr
#29 medi*
#30 #24 or #25 or #26 or #27 or #28 or #29
#31 #4 and #23 and #30
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Web of Science Social Science Citation Index and Conference Proceedings
#19 #3 AND #13 AND #18
DocType=All document types; Language=All languages;
#18 #17 OR #16 OR #15 OR #14
DocType=All document types; Language=All languages;
#17 TS=(medi*) OR TI=(medi*)
DocType=All document types; Language=All languages;
#16 TOPIC: (pcr) OR TITLE: (pcr)
DocType=All document types; Language=All languages;
#15 TOPIC: (polymerase chain reaction) OR TITLE: (polymerase chain reaction)
DocType=All document types; Language=All languages;
#14 TOPIC: (cultur*) OR TITLE: (cultur*)
DocType=All document types; Language=All languages;
#13 #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4
DocType=All document types; Language=All languages;
#12 TOPIC: (unborn* or unborn*) OR TITLE: (unborn* or unborn*)
DocType=All document types; Language=All languages
#11 TOPIC: (deliver*) OR TITLE: (deliver*)
DocType=All document types; Language=All languages;
#10 TOPIC: (antepartum* or ante-partum*) OR TITLE: (antepartum* or ante-partum*)
DocType=All document types; Language=All languages;
#9 TOPIC: (intrapartum* or intra-partum*) OR TITLE: (intrapartum* or intra-partum*)
DocType=All document types; Language=All languages;
#8 TOPIC: (prenatal* or pre-natal*) OR TITLE: (prenatal* or pre-natal*)
DocType=All document types; Language=All languages;
#7 TOPIC: (antenatal*) OR TITLE: (antenatal*)
DocType=All document types; Language=All languages;
#6 TOPIC: (labour* or labor*) OR TITLE: (labour* or labor*)
DocType=All document types; Language=All languages;
#5 TOPIC: (birth*) OR TITLE: (birth*)
DocType=All document types; Language=All languages;
#4 TOPIC: (pregnan*) OR TITLE: (pregnan*)
DocType=All document types; Language=All languages;
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(Continued)
#3 #2 OR #1
DocType=All document types; Language=All languages;
#2 TOPIC: (strep* adj2 b) OR TITLE: (strep* adj2 b)
DocType=All document types; Language=All languages;
#1 TOPIC: (strep* adj2 agalact*) OR TITLE: (strep* adj2 agalact*)
DocType=All document types; Language=All languages;
CINAHL Ebscohost
Search Terms Search Options
S33 S3 AND S25 AND S32
S32 S26 OR S27 OR S28 OR S29 OR S30 or S31
S31 TI medi* OR AB medi*
S30 TI pcr OR AB pcr
S29 TI polymerase chain reaction OR AB polymerase chain reaction
S28 TI cultur* OR AB cultur*
S27 (MH “Nucleic Acid Amplification Techniques+”)
S26 (MH “Culture Media”)
S25 S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR
S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR 24
S24 TI unborn* OR AB unborn*
S23 TI birth* OR AB birth*
S22 TI deliver* OR AB deliver*
S21 TI antepartum OR AB antepartum
S20 TI intrapartum OR AB intrapartum
S19 (MH “Intrapartum Care+”)
S18 TI pre-natal OR AB pre-natal
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(Continued)
S17 TI prenatal OR AB prenatal
S16 TI antenatal OR AB antenatal
S15 TI labor OR AB labor
S14 TI labour OR AB labour
S13 TI pregnan* OR AB pregnan*
S12 (MH “Health Screening”)
S11 (MH “Labor Complications”)
S10 (MH “Pregnancy Complications, Infectious”)
S9 (MH “Delivery, Obstetric+”)
S8 (MH “Prenatal Diagnosis+”)




S3 S1 OR S2
S2 TI strep* adj2 agalact* OR AB strep* adj2 agalact*
S1 TI strep* adj2 b OR AB strep* adj2 b
Appendix 2. Application of QUADAS-2 for methodological quality assessment of included studies
QUADAS-2 is structured checklist consisting of 4 domains: patient selection, index test, reference standard, and flow and timing. Each
domain is rated in terms of risk of bias and three of the domains are also rated in terms of concern regarding applicability to the review
question. Each key domain has a set of signalling questions to help reach the judgments regarding bias and applicability. The table
below outlines how QUADAS-2 will be applied in this review.
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DOMAIN 1: PATIENT SELECTION
A. Risk of Bias
Describe methods of patient selection:
+ Was a consecutive or random sample of patients enrolled? Yes/No/
Unclear
· Yes: if all eligible patients were enrolled; or if the authors reported that the patients were either a consecutive series or randomly
selected;
· No: if the authors reported that the selection was based on clinical judgement of health workers, or participation of randomly
selected people in the study was low;
· Unclear: if there is discrepancy between the numbers of eligible people and the number of included people, but no reasons given
for that, or the selection procedure is not clearly described
+ Did the study avoid inappropriate exclusions? Yes/No/
Unclear
· Yes: if no patients were excluded before enrolment, OR explanation was given for excluded participants and the reason is deemed
appropriate e.g. participant had an elective caesarean section, participant had intrapartum antibiotic prophylaxis before reference
standard
· No: if patients were excluded before enrolment and no explanation was given or the explanation is unacceptable, e.g. exclusions
based on age, ethnicity, multiple pregnancies
· Unclear: if insufficient information is provided to make a judgement, for example, it is unclear if or why patients were excluded





B. Concerns regarding applicability
Describe included patients (prior testing, presentation, intended use of index test and setting):






· High concern: if the study population does not resemble a population that would be considered for a GBS screening programme in
practice;
· Low concern: if the study population does resemble a population that would be considered for a GBS screening programme in
practice;
· Unclear: if not reported or insufficient information is provided to decide
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DOMAIN 2: INDEX TEST(S)
If more than one index test was evaluated in a study, the domain will be completed for each test.
A. Risk of Bias
Describe the index test and how it was conducted and interpreted:
+ Were the index test results interpreted without knowledge of the results of the reference standard? Yes/No/Unclear
· Yes: if the screening test was interpreted without knowing the reference standard intrapartum or newborn GBS culture result
· No: if the screening test was interpreted with knowledge of the reference standard intrapartum or newborn GBS culture result
· Unclear: if insufficient information is provided to decide. For example, if it was unclear whether the interpreter was blinded to the
results of the reference test or if they were ‘usually’ blinded
+If a threshold was used, was it pre-specified? Yes/No/Unclear
· Yes: if the methods or referenced manual state this threshold
· No: if the methods or referenced manual do not state this threshold
· Unclear: if insufficient information is provided to decide
Could the conduct or interpretation of the index test have introduced bias? RISK: LOW/HIGH/UNCLEAR
B. Concerns regarding applicability
Describe who processed the real-time PCR test and interpreted the result
Is there concern that the index test, its conduct, or interpretation differs from the
review question?
CONCERN: LOW/HIGH/UNCLEAR
Who processes the real-time PCR test and who interprets the result has important implications on its clinical applicability to labour
wards
· High concern: if test can only be processed in the laboratory due to equipment required or test can be processed in labour wards
but was processed in the laboratory by laboratory staff in the study
· Low concern: if midwives on labour wards processed the test and interpreted the result
· Unclear concern: if not reported or insufficient information is provided to decide
DOMAIN 3: REFERENCE STANDARD(S)
A. Risk of Bias
Describe the reference standard and how it was conducted and interpreted:
+Were reference standard results interpretedwithout knowledge of the results
of the index test?
Yes/No/Unclear
· Yes: if the screening test results were not known to the people interpreting the intrapartum or newborn culture reference standard
results;
·No: if the screening test results were known to the people interpreting the intrapartum or newborn culture reference standard results;
· Unclear: if insufficient information is provided to decide
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+ Is the reference standard likely to correctly identify GBS coloni-
sation/disease?
Yes/No/Unclear
· Yes: if the reference standard was intrapartum selective enrichment culture from a vaginal and rectal swab (combined vagino-rectal
or separate vaginal and rectal swabs processed together) for GBS maternal colonisation; newborn selective enrichment culture from
any surface swab for neonatal GBS colonisation; newborn culture from blood, CSF, or another sterile site for GBS neonatal disease
· No: if the reference standard was intrapartum culture from a vaginal or rectal swab alone or culture without selective enrichment for
GBS maternal colonisation; newborn culture was without selective enrichment for neonatal GBS colonisation; and newborn culture
for GBS neonatal disease was not from a sterile site
· Unclear: if insufficient information is provided to decide
Could the reference standard, its conduct, or its
interpretation have introduced bias?
RISK: LOW/HIGH/UNCLEAR
B. Concerns regarding applicability
Is there concern that the target condition
as defined by the reference standard does
not match the review question?
CONCERN: LOW/HIGH/UNCLEAR
DOMAIN 4: FLOW AND TIMING
A. Risk of Bias
Describe any patients who did not receive the index test(s) and/or reference standard or who were excluded from the 2x2 tables:
Describe the time interval and any interventions between index test(s) and reference standard:
+ Did all women or newborns
receive the same reference stan-
dard?
Yes/No/Unclear
· Yes: if all enrolled patients in the 2x2 tables received the same reference standard
· No: if all patients in the 2x2 tables did not receive the same reference standard
· Unclear: if insufficient information is provided to decide




· Yes: if all enrolled participants were included in the 2x2 tables and no patients withdrew (all received the index and reference test)
and data was available for all, OR reasons for withdrawal (not receiving both index and/or reference test) /missing data (e.g. invalid
result or missing from records) were explained. ‘Missing data’ is not acceptable; needs to explain why
·No: if enrolled participants were excluded from 2x2 table but their reasons for withdrawal (not receiving both index and/or reference
test) or missing data (e.g. invalid result or missing from records) are not explained. Nothing is said about potential withdrawals or if
it appears that some participants who entered the study did not complete the study, and these participants are not accounted for
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Guidance for when to score a domain as high, low, or unclear risk of bias:
Domain 1, Patient selection: Any one ‘No’ means that the domain is at high risk of bias, as the way participants were recruited,
and who may have been excluded, are important sources of bias. Any one ‘Unclear’ means that the domain is at unclear risk of bias.
Otherwise the domain is at low risk of bias.
Domain 2, Index test: If the question regarding threshold is scored ‘No’, the domain will be at high risk of bias. If the question
regarding threshold is scored ‘Unclear’, the domain will be at unclear risk of bias. Otherwise the domain is at low risk of bias. The
question on blinding is not a high concern as reference standard results cannot physically be available when interpreting the index tests.
Domain 3, Reference standard: If the question regarding blinding is scored ‘No’, the domain will be at high risk of bias. If the question
regarding blinding is scored ‘Unclear, the domain will be at unclear risk of bias. Otherwise the domain is at low risk of bias. The
question on correct identification is not a high concern because there is uncertainty whether selective enrichment is required, and the
impact that the different testing methods may have on accuracy will be assessed in the investigations of heterogeneity and sensitivity
analyses.
Domain 4, Flow and timing: Any one ‘No’ means the domain is at high risk of bias, as both sources of bias are important, e.g. if some
participants had an ear swab while others had a neck swab OR missing data and withdrawals were not explained. Otherwise any one
‘Unclear’ means that the domain is at unclear risk of bias. Otherwise the domain is at low risk of bias.
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